Neuron Systems Inc., Burlington, Massachusetts (an investment of Johnson & Johnson Development Corporation and Domain Associates) and pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Massachusetts, have announced a deal to evaluate pSivida’s “Durasert” bioerodible implantable delivery device system in combination with compounds from Neuron to treat dry age-related macular degeneration (AMD). The Technology Evaluation Agreement will govern the development of a sustained release drug delivery product for the treatment of back-of-the-eye diseases. Iluvien, pSivida’s most advanced product candidate, referenced in EURETINA Brief’s Clinical/Regulatory section, is licensed to Alimera Sciences, Inc., and will shortly enter national approval stage in the EU under the EU’s Decentralized Procedure (DCP). pSivida has also developed two FDA-approved products, Retisert, for the treatment of posterior uveitis and Vitrasert, for the treatment of AIDS-related cytomegalovirus (CMV) retinitis.